Elekta unveiled plans to acquire Milan, Italy-based 3D Line Medical Systems. Elekta stands to gain an R &D group specialized in stereotactic radiosurgery and dynamic IMRT treatments as well as a product portfolio of advanced equipment and treatment planning software systems for performing radiation therapy. Once approved, Elekta will pay $13.3 million in cash for the company’s assets and possibly as much as an additional $10.6 million if certain performance goals are met in the next three years. Elekta expects to consolidate 3D Line into its operations starting May 1.
Among the 3D Line’s technologies are the ERGO, a specialized treatment planning system for stereotactic radiation therapy and dynamic IMRT, and also the DYNART series of micro-sized multi leaf collimators.
3D Line technology has already been integrated in Elekta Axesse, an advanced robotic image guided stereotactic treatment management system. 3D Line technology will form a platform for further integration and development to meet the demand from advanced radiation oncology programs for integrated, open architecture systems, Elekta said.